Rapid ADC Partnerships Araris' linker technology enables attaching payloads to off-the-shelf antibodies without antibody engineering, offering pharmacology teams a faster path to ADC candidates. This creates sales opportunities with large and mid-size pharma/biotech companies seeking faster times-to-clinic and reduced upfront R&D risk through licensing or co-development agreements.

M&A Momentum Recent high-profile acquisition activity and partnerships around Araris signal strong strategic value and buyer interest in ADC platforms. This presents opportunities for licensing deals, strategic collaborations, or preemptive outreach to potential acquirers to monetize the platform before or during an exit.

Credibility Validation As a spin-off from Paul Scherrer Institute and ETH and recipient of industry recognition, Araris has credible scientific pedigree that can lower customer risk perceptions. Use this validation to engage risk-averse decision-makers in pharma and to accelerate discussions on pilot collaborations and sponsored research.

Clinical Collaboration With a Phase 1 clinical trial in collaboration with Taiho, Araris is positioned to attract development-stage partners for joint clinical programs, API supply, or CMC manufacturing collaboration, including scale-up and payload optimization using the linker platform.

European Access Based in Zurich with connections to European research ecosystems, Araris offers a gateway for European CROs, PK/PD and regulatory teams, enabling partnerships for regional trials and co-development deals with European pharma companies seeking to leverage EU trials and local expertise.